Evaluating Clobetasol Propionate Mouthwash and Photobiomodulation Therapy for Oral Lesions in Pemphigus Vulgaris Patients
Led by Damascus University · Updated on 2026-06-11
30
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Pemphigus vulgaris PV is a chronic autoimmune disorder that causes painful oral lesions and significantly reduces quality of life. This trial studies the effectiveness and safety of supportive topical treatments, including clobetasol propionate 0.05% mouthwash, photobiomodulation therapy PBMT, and their combination. The goal is to find topical therapies that help heal oral erosions, reduce pain, and potentially lower the need for systemic medications, thereby improving patient outcomes.
Participants receive one of three treatments clobetasol propionate 0.05% mouthwash used three times daily for 3 minutes over 4 weeks with gradual tapering, PBMT delivered by a 650 nm diode laser twice weekly for 30 days, or a combination of both treatments given simultaneously. The laser treatment is non-invasive and applied without contact to the lesions. All treatments are administered according to standardized protocols.
During the study, participants are followed with assessments on Days 7, 14, 21, 28, 42, 60, and 90. Researchers will measure disease severity using scores like the Pemphigus Disease Area Index and Oral Disease Severity Score, track corticosteroid dosages, and evaluate quality of life and anxiety or depression scales. The trial includes safety monitoring and aims to observe the healing progress and impact on systemic medication use over three months.
CONDITIONS
Brief Title
Comparison of the Efficacy of Clobetasol Propionate 0.05% Mouthwash, Photobiomodulation, and Their Combination in Managing of Oral Lesions in Patient With Pemphigus Vulgaris.
Research Team
A
Alaa Alhomsi, DDS,MSc,PhD Student
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Confirmed diagnosis of pemphigus vulgaris based on clinical, histopathological, and immunopathological findings
Presence of active erosive or ulcerative oral lesions larger than 1 cm
Stable systemic corticosteroid treatment not exceeding 1 mg/kg/day
You will not qualify if you...
Presence of significant chronic systemic diseases such as gastrointestinal disorders or uncontrolled diabetes
History or current diagnosis of cancer
Use of systemic antibiotics, NSAIDs, or hormonal therapies that may affect study results
Pregnancy or active breastfeeding
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 4 weeks
Participants receive one of three treatments: clobetasol propionate 0.05% mouthwash three times daily for 4 weeks with gradual tapering, photobiomodulation therapy twice weekly for 30 days, or a combination of both. Treatments are administered by trained clinicians following standardized protocols.
Multiple visits during treatment period
Follow-up
Duration - Up to 90 days after treatment
Participants are monitored with scheduled assessments on Days 7, 14, 21, 28, 42, 60, and 90 to evaluate disease severity, steroid use, quality of life, and mental health scales.
Seven follow-up visits
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Macroscopic and microscopic effects of GaAIAs diode laser and dexamethasone therapies on oral mucositis induced by fluorouracil in rats.
Renata Nemetala Lara, Eliete Neves Silva da Guerra, Nilce Santos de Melo
Randomized double-blind clinical trial comparing clobetasol and dexamethasone for the topical treatment of symptomatic oral chronic graft-versus-host disease.
Cesar W Noce, Alessandra Gomes, Vanessa Shcaira...
Combined treatment of dexamethasone mouthwash and low-level laser therapy in the management of aphthous-like ulcers caused by nonsteroidal anti-inflammatory drugs: A case report.